The Greater Cannabis Company, Inc. (GCAN)

GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy. The Company had previously announced the preclinical study as part of its license and research agreement with Shaare Zedek Scientific related